 |
Our principals have raised in excess of $2 billion* of private equity for public and private
life science companies.
Investors in our financings have included institutional investors, venture capitalists, mezzanine investors, and strategic corporate investors in the United States, Canada, Europe and Asia. Investors know that we have associated ourselves with high-quality companies, opportunities and management teams.
|